Sirukumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IL6 |
| Clinical data | |
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6450H9926N1690O1998S46 |
| Molar mass | 144588.95 g·mol−1 |
  (what is this?) | |
Sirukumab (INN, USAN) (developmental code name CNTO-136) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.[1] It acts against the proinflammatory cytokine Interleukin 6 (IL-6).
Sirukumab is currently under development by Johnson & Johnson's subsidiary Centocor[2]
Clinical trials[]
Rheumatoid arthritis[]
It has started clinical trials.[3] and reported some phase II results.[2]
In December 2015 three phase III trials (SIRROUND-D, -H and -T) were collecting data.[4] By Feb 2017 SIRROUND-D was considered to have met both co-primary endpoints.[5]
Other[]
The drug is currently in phase II clinical trials for the treatment of depression.[6]
See also[]
References[]
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab" (PDF). American Medical Association.
- ^ a b Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
- ^ A Study of the Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy, clinicaltrials.gov
- ^ Glaxo says top-line results positive in late-stage study of sirukumab in rheumatoid arthritis. Dec 2015
- ^ IL-6 in RA: What Predicts Non-Progression? - High-risk patients showed most benefit with sirukumab. Jan 2017
- ^ adisinsight
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by . |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by . |
- Antidepressants
- Janssen Biotech
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs